Form 4: United Therapeutics CEO Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 25 and 26, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On July 25 and 26, 2024, Rothblatt exercised stock options and sold shares of United Therapeutics common stock.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- The exercise price for the stock options was $129.49 per share.
- The sales prices ranged from $333.9273 to $343.7887 per share on July 25 and from $336.9522 to $339.784 on July 26.
- A total of 7,200 stock options were exercised and 7,200 shares were sold over the two days.
- Following these transactions, Rothblatt directly owns 464 shares of common stock.
- Rothblatt also indirectly owns shares through various family trusts.
Sentiment
Score: 5
Explanation: The document is a routine filing related to stock option exercises and sales by the CEO under a pre-arranged plan. It doesn't contain any information that would significantly impact the company's valuation positively or negatively.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of a tranche of 723,869 stock options expiring on December 31, 2024.
Industry Context
Executive stock sales are common and often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- 10b5-1 trading plans are a standard practice among corporate executives to manage their stock holdings and avoid insider trading concerns.
- The size and frequency of stock option exercises and sales can vary widely depending on the company, the executive's compensation package, and their personal financial planning.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Date exercisable for stock options |
| 08/04/2023 | Date the 10b5-1 trading plan was entered into. |
| 07/25/2024 | Date of first reported transaction (exercise and sale of stock options). |
| 07/26/2024 | Date of second reported transaction (exercise and sale of stock options). |
| 08/31/2024 | End date of the 10b5-1 trading plan (or earlier exhaustion of options). |
| 12/31/2024 | Expiration date of the tranche of 723,869 stock options. |
| 07/29/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.